Imeglimin Protects Islets From Hypoxia via Mitochondrial Preservation and ROS Reduction, Improving Early Graft Survival

Imeglimin is a metformin-derived antidiabetic drug that improves glycemia by optimizing mitochondrial function. Evidence suggests it enhances mitochondrial efficiency and preserves pancreatic β-cell mass (BCM) under diabetic stress. However, its protective effect against hypoxia-induced islet damage, a key cause of early β-cell loss after transplantation, remains unclear. We investigated the effect of imeglimin on hypoxia-induced mitochondrial dysfunction in islets and assessed its impact on an intramuscular islet transplantation model. Under 5% O2, imeglimin preserved mitochondrial membrane potential and normalized reactive oxygen species (ROS) levels, whereas metformin alone failed to reduce ROS. Combined treatment showed complementary mitochondrial protection. Transcriptomic analysis identified restoration of Cox6a2 and attenuation of hypoxia-associated YAP/TAZ target gene signature. In vivo, imeglimin recipients showed improved glycemic control and glucose tolerance, and indium-111-labeled exendin-4 single-photon emission computed tomography/computed tomography confirmed greater graft BCM on day 14. Early graft histology revealed reduced apoptosis, oxidative stress marker presence, and HIF1A accumulation, alongside preserved TOMM20 and COX6A2 expression in the imeglimin group. Imeglimin protected pancreatic islets from hypoxia-associated mitochondrial dysfunction, in association with restoration of Cox6a2 expression, and improved early outcomes of intramuscular islet transplantation. These findings support imeglimin as a potential adjunct therapy to preserve islet grafts during the early hypoxic phase after transplantation. ARTICLE HIGHLIGHTS: Imeglimin improves mitochondrial function and preserves β-cells, but its ability to counter hypoxia-induced mitochondrial dysfunction, a key cause of early islet graft loss, has not been established. Under hypoxic conditions, imeglimin preserved mitochondrial membrane potential while suppressing reactive oxygen species (ROS) production and mitophagy; in contrast, metformin did not reduce ROS, indicating a distinct mitochondrial stress-response profile. Transcriptomics implicate restoration of Cox6a2 expression and attenuation of hypoxia-associated YAP/TAZ target gene signatures as potential mechanisms underlying mitochondrial protection. In vivo, short-term imeglimin administration improved glycemic control and preserved graft β-cell mass, as assessed by indium-111-labeled exendin-4 single-photon emission computed tomography/computed tomography imaging, accompanied by reduced apoptosis and oxidative stress within graft tissue.

Authors

Institutions

Publication Details

Journal
Diabetes
Published
2026-11-18
DOI
https://doi.org/10.2337/db26-0360
Primary Topic
Pancreatic function and diabetes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Imeglimin Protects Islets From Hypoxia via Mitochondrial Preservation and ROS Reduction, Improving Early Graft Survival

Toshinori Imaizumi, Daisuke Otani, Takaaki Murakami, Daisuke Yabe et al.
2 links
Diabetes
Pancreatic function and diabetes
article

Imeglimin Protects Islets From Hypoxia via Mitochondrial Preservation and ROS Reduction, Improving Early Graft Survival

Toshinori Imaizumi, Daisuke Otani, Takaaki Murakami, Daisuke Yabe, Muhammad Ihsan Fauzi, Mari Matsushiro, Hiroyuki Fujimoto, Hayao Yoshida, Kentarou Sakaki, Nobuki Isogai, Ryuto Terao, Na Ren
article en

Abstract

Imeglimin is a metformin-derived antidiabetic drug that improves glycemia by optimizing mitochondrial function. Evidence suggests it enhances mitochondrial efficiency and preserves pancreatic β-cell mass (BCM) under diabetic stress. However, its protective effect against hypoxia-induced islet damage, a key cause of early β-cell loss after transplantation, remains unclear. We investigated the effect of imeglimin on hypoxia-induced mitochondrial dysfunction in islets and assessed its impact on an intramuscular islet transplantation model. Under 5% O2, imeglimin preserved mitochondrial membrane potential and normalized reactive oxygen species (ROS) levels, whereas metformin alone failed to reduce ROS. Combined treatment showed complementary mitochondrial protection. Transcriptomic analysis identified restoration of Cox6a2 and attenuation of hypoxia-associated YAP/TAZ target gene signature. In vivo, imeglimin recipients showed improved glycemic control and glucose tolerance, and indium-111-labeled exendin-4 single-photon emission computed tomography/computed tomography confirmed greater graft BCM on day 14. Early graft histology revealed reduced apoptosis, oxidative stress marker presence, and HIF1A accumulation, alongside preserved TOMM20 and COX6A2 expression in the imeglimin group. Imeglimin protected pancreatic islets from hypoxia-associated mitochondrial dysfunction, in association with restoration of Cox6a2 expression, and improved early outcomes of intramuscular islet transplantation. These findings support imeglimin as a potential adjunct therapy to preserve islet grafts during the early hypoxic phase after transplantation. ARTICLE HIGHLIGHTS: Imeglimin improves mitochondrial function and preserves β-cells, but its ability to counter hypoxia-induced mitochondrial dysfunction, a key cause of early islet graft loss, has not been established. Under hypoxic conditions, imeglimin preserved mitochondrial membrane potential while suppressing reactive oxygen species (ROS) production and mitophagy; in contrast, metformin did not reduce ROS, indicating a distinct mitochondrial stress-response profile. Transcriptomics implicate restoration of Cox6a2 expression and attenuation of hypoxia-associated YAP/TAZ target gene signatures as potential mechanisms underlying mitochondrial protection. In vivo, short-term imeglimin administration improved glycemic control and preserved graft β-cell mass, as assessed by indium-111-labeled exendin-4 single-photon emission computed tomography/computed tomography imaging, accompanied by reduced apoptosis and oxidative stress within graft tissue.

Diabetes
Kyoto University (JP), Kyoto University Hospital (JP)
Japan Foundation for Applied Enzymology, Japan Association for Diabetes Education and Care, Japan IDDM network, Japan Society for the Promotion of Science
Good health and well-being
Pancreatic function and diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon